There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price
May 18
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 20, 2025
DataAggregated Company Financials
Companies565
- 7D0.8%
- 3M-9.3%
- 1Y-13.8%
- YTD-5.7%
Over the last 7 days, the Biotech industry has remained flat, although notably Alnylam Pharmaceuticals gained 9.4%. As for the longer term, the industry has declined 14% in the last year. Earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 20 May 2025 | US$895.3b | US$155.9b | -US$24,383,038,329.03 | 16.1x | -36.7x | 5.7x |
| Thu, 17 Apr 2025 | US$763.1b | US$119.2b | -US$36,649,632,928.05 | 19.4x | -20.8x | 6.4x |
| Sat, 15 Mar 2025 | US$834.3b | US$118.4b | -US$37,624,196,989.93 | 18.5x | -22.2x | 7x |
| Mon, 10 Feb 2025 | US$840.3b | US$117.3b | -US$30,891,273,158.04 | 17.2x | -27.2x | 7.2x |
| Wed, 08 Jan 2025 | US$967.5b | US$149.6b | -US$26,358,490,111.72 | 16.5x | -36.7x | 6.5x |
| Fri, 06 Dec 2024 | US$1.0t | US$150.0b | -US$26,562,709,685.06 | 17.5x | -38.7x | 6.9x |
| Sun, 03 Nov 2024 | US$1.1t | US$147.4b | -US$30,522,373,860.52 | 17.5x | -35x | 7.2x |
| Tue, 01 Oct 2024 | US$894.5b | US$113.2b | -US$36,002,779,251.24 | 21.3x | -24.8x | 7.9x |
| Thu, 29 Aug 2024 | US$907.1b | US$113.1b | -US$35,726,620,298.35 | 24.2x | -25.4x | 8x |
| Sat, 27 Jul 2024 | US$1.2t | US$164.9b | -US$28,965,808,648.76 | 26.4x | -42.6x | 7.5x |
| Mon, 24 Jun 2024 | US$1.2t | US$164.4b | -US$27,942,490,934.12 | 28.1x | -41.4x | 7x |
| Wed, 22 May 2024 | US$1.1t | US$164.6b | -US$26,765,333,205.64 | 24.5x | -42.8x | 7x |
| Fri, 19 Apr 2024 | US$1.1t | US$164.2b | -US$23,337,120,518.73 | 20.4x | -45.9x | 6.5x |
| Sun, 17 Mar 2024 | US$1.2t | US$167.4b | -US$22,071,849,383.64 | 13.9x | -53.2x | 7x |
| Tue, 13 Feb 2024 | US$1.2t | US$169.3b | -US$26,222,327,301.15 | 20.4x | -44.5x | 6.9x |
| Thu, 11 Jan 2024 | US$1.4t | US$204.8b | -US$22,494,732,823.00 | 19.3x | -64.2x | 7.1x |
| Sat, 09 Dec 2023 | US$1.3t | US$204.6b | -US$22,091,414,218.00 | 18.7x | -58.4x | 6.3x |
| Mon, 06 Nov 2023 | US$1.2t | US$206.7b | -US$20,529,146,956.00 | 18.8x | -60.5x | 6x |
| Wed, 04 Oct 2023 | US$1.2t | US$207.3b | -US$13,085,561,707.00 | 16.6x | -94.9x | 6x |
| Fri, 01 Sep 2023 | US$1.3t | US$207.6b | -US$12,418,173,316.00 | 17.4x | -103.3x | 6.2x |
| Sun, 30 Jul 2023 | US$1.1t | US$186.0b | -US$15,177,418,533.00 | 14.7x | -74.9x | 6.1x |
| Tue, 27 Jun 2023 | US$1.1t | US$186.2b | -US$16,151,917,994.00 | 13.4x | -69.8x | 6.1x |
| Thu, 25 May 2023 | US$1.1t | US$185.9b | -US$15,950,003,280.00 | 11.5x | -71.8x | 6.2x |
| Sat, 22 Apr 2023 | US$1.2t | US$198.4b | -US$3,214,788,122.00 | 13.9x | -370.1x | 6x |
| Mon, 20 Mar 2023 | US$1.1t | US$199.2b | -US$3,870,392,033.00 | 13.2x | -288.7x | 5.6x |
| Wed, 15 Feb 2023 | US$1.2t | US$202.8b | -US$166,103,827.00 | 16.3x | -6973.2x | 5.7x |
| Fri, 13 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.5x | 658.8x | 5.8x |
| Sun, 11 Dec 2022 | US$1.1t | US$202.7b | US$1.4b | 14.6x | 811.7x | 5.6x |
| Tue, 08 Nov 2022 | US$1.1t | US$204.5b | US$3.9b | 14.4x | 280.2x | 5.3x |
| Thu, 06 Oct 2022 | US$1.1t | US$206.3b | US$5.5b | 15.3x | 193.7x | 5.2x |
| Sat, 03 Sep 2022 | US$1.0t | US$206.4b | US$6.2b | 14.6x | 168.2x | 5x |
| Mon, 01 Aug 2022 | US$1.1t | US$212.0b | US$11.3b | 15.6x | 93.2x | 5x |
| Wed, 29 Jun 2022 | US$1.0t | US$212.3b | US$11.0b | 15.6x | 94.1x | 4.9x |
| Fri, 27 May 2022 | US$1.0t | US$212.6b | US$11.1b | 15.4x | 90.6x | 4.7x |
Price to Earnings Ratio
90.6x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.8% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.58% | |
| Healthcare | -1.01% | |
| Biotech | 0.80% | |
| Biotech | 0.80% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | US$291.86 | 9.4% +US$3.3b | 95.1% | PS16.2x | |
| GILD Gilead Sciences | US$106.16 | 2.3% +US$2.9b | 56.3% | PE22.1x | |
| REGN Regeneron Pharmaceuticals | US$596.54 | 3.6% +US$2.2b | -39.6% | PE14x | |
| EXEL Exelixis | US$44.69 | 20.8% +US$2.0b | 112.2% | PE18.9x | |
| ACAD ACADIA Pharmaceuticals | US$21.99 | 25.5% +US$748.1m | 45.6% | PE16.1x |
